SCHEMBL43564

SCHEMBL43564

O=C1c2ccc3ccccc3c2C(=O)N1O.[NaH]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.49
ERCC1 P07992 2/20 0.47
FEN1 P39748 2/20 0.47
ERCC4 Q92889 2/20 0.47
POLB P06746 3/20 0.44
MAPT P10636 3/20 0.44
CYP1A2 P05177 2/20 0.44
ALOX12 P18054 2/20 0.44
TSHR P16473 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
PRKCA P17252 1/20 0.42
WDR5 P61964 1/20 0.42
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 3/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567138 0.98 DNMT1 (0.50) DNMT1ERCC1FEN1ERCC4POLB
SCHEMBL65123 0.85 TSHR (0.44) DNMT1ERCC1FEN1ERCC4POLB
Trifluoromethanesulfonic Acid SCHEMBL51718 0.85 DNMT1 (0.43) DNMT1ERCC1FEN1ERCC4POLB
SCHEMBL3144814 0.81 ALDH1A1 (0.48) DNMT1MAPTCYP1A2TDP1KMT2A
SCHEMBL6734024 0.76 DNMT1 (0.50) DNMT1POLBMAPTCYP1A2ALOX12
SCHEMBL4104478 0.76 DNMT1 (0.50) DNMT1POLBMAPTCYP1A2ALOX12
SCHEMBL4109839 0.76 DNMT1 (0.50) DNMT1POLBMAPTCYP1A2ALOX12
SCHEMBL8407062 0.76 DNMT1 (0.50) DNMT1POLBMAPTCYP1A2ALOX12
SCHEMBL10426593 0.76 DNMT1 (0.50) DNMT1POLBMAPTCYP1A2ALOX12
SCHEMBL11877346 0.76 DNMT1 (0.46) DNMT1POLBMAPTCYP1A2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2022-01-04 US disclosed
EP-3327003-B1 PROCESS FOR CONCENTRATING A MIXTURE CONTAINING ORGANIC HYDROPEROXIDE EXXONMOBIL CHEMICAL PATENTS INC (US) 2020-09-16 EP disclosed
CN-106716252-B Photosensitive resin composition, cured film and method for producing same, liquid crystal display device, organic electroluminescence display device, and touch panel 富士胶片株式会社 2020-01-07 CN disclosed
CN-106687865-B TFT substrate, organic EL display device, and method for manufacturing liquid crystal display device 富士胶片株式会社 2020-01-03 CN disclosed
EP-3180304-B1 PROCESS FOR PRODUCING CYCLOHEXANONE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-10-30 EP disclosed
US-20190283002-A1 Dehydrogenation Catalysts and Methods of Making and Using the Same EXXONMOBIL CHEMICAL PATENTS INC. 2019-09-19 US disclosed
EP-3013779-B1 PROCESS FOR PRODUCING PHENOL AND/OR CYCLOHEXANONE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-07-31 EP disclosed
EP-3013795-B1 PROCESS FOR CONCENTRATING A MIXTURE CONTAINING ORGANIC HYDROPEROXIDE EXXONMOBIL CHEMICAL PATENTS INC (US) 2019-07-24 EP disclosed
US-10351506-B2 Purified plasticizers, production and use EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-07-16 US disclosed
US-20190176131-A1 Methods of Making Supported Mixed Metal Dehydrogenation Catalysts EXXONMOBIL CHEMICAL PATENTS INC. 2019-06-13 US disclosed
US-6348475-B1 POLYMERASE INHIBITOR GUILFORD PHARMACEUTICALS INC. 2002-02-19 US disclosed
US-20020019417-A1 Methods, compounds and compositions for treating gout EISAI INC. 2002-02-14 US disclosed
WO-2001091796-A2 METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT GUILFORD PHARMACEUTICALS INC. (US) 2001-12-06 WO disclosed
US-6297403-B1 OXIDATION OF A (DI)ARYL METHANE OR METHYLENE DERIVATIVE IN PRESENCE OF AN AMINE OXIDE OR HYDROXYAMINE DERIVATIVE MEDIATOR; BY-PRODUCT INHIBITION Consortium für elektrochemische Industrie GmbH (DE) 2001-10-02 US disclosed
US-6242245-B1 DELIGNIFICATION BY ADDING SUSPENSION OF LACCASE, OXIDANT, MEDIATOR SUCH AS VIOLURIC ACID, AND XYLANASE TO AQUEOUS SUSPENSION OF LIGNIN MATERIAL AND MIXING; MEDIATOR DOES NOT DEACTIVATE ENZYME Consortium für elektrochemische Industrie GmbH (DE) 2001-06-05 US disclosed
US-6187170-B1 SYSTEM FOR THE ELECTROCHEMICAL CLEAVAGE OF COMPOUNDS WHICH INCLUDES A MEDIATOR AND AT LEAST TWO ELECTRODES FOR THE ELECTROCHEMICAL ACTIVATION OF THE MEDIATOR Consortium für elektrochemische Industrie GmbH (DE) 2001-02-13 US disclosed
US-6169213-B1 REACTING A HETEROARYL METHANOL WITH AN OXIDANT AND A MEDIATOR CONTAINING AMINO OXIDE GROUP TO FORM HETEROARYL ALDEHYDE OR A HETEROARYL KETONE Consortium f{umlaut over (u)}r elektrochemische Industrie GmbH (DE) 2001-01-02 US disclosed
US-6069282-A REACTION OF VINYL-, ALKYNYL- OR ARYL-METHANOLS WITH THE AID OF A MEDIATOR AND AN OXIDANT, WHEREIN THE MEDIATOR IS SELECTED FROM THE GROUP OF THE ALIPHATIC, CYCLOALIPHATIC, HETEROCYCLIC OR AROMATIC NO OR NOH CONTAINING COMPOUNDS CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 2000-05-30 US disclosed
US-6023000-A Process for the preparation of aldehydes and ketones Consortium fur elektrochemisch Industrie GmbH (DE) 2000-02-08 US disclosed
WO-1999008680-A1 METHOD OF USING SELECTIVE PARP INHIBITORS TO PREVENT OR TREAT NEUROTOXICITY THE JOHNS HOPKINS UNIVERSITY (US) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11213804-B2 Dehydrogenation catalysts and methods of making and using the same IDH2, ADH4, IDH1 DNMT1 51/4885ERCC1 1492/4885FEN1 448/4885
US-10351506-B2 Purified plasticizers, production and use ALKBH3, FTO, ALK DNMT1 363/4885ERCC1 625/4885FEN1 494/4885
US-20190176131-A1 Methods of Making Supported Mixed Metal Dehydrogenation Catalysts SOD1, DNMT1, CA1 DNMT1 2/4885ERCC1 1224/4885FEN1 389/4885
US-20020019417-A1 Methods, compounds and compositions for treating gout PARP2, PARP1, PARP3 DNMT1 1772/4885ERCC1 139/4885FEN1 201/4885
US-20190283002-A1 Dehydrogenation Catalysts and Methods of Making and Using the Same IDH2, ADH4, IDH1 DNMT1 51/4885ERCC1 1492/4885FEN1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.